mayo clinic glp-1 program Healthy weight loss when GLP-1s are not an option Mayo Clinic researchers have developed

Postgrad Med J 96(1133):156161 [DOI] [PMC free article] [PubMed] [Google Scholar] Singh K, Aulakh SK, Nijjar GS, Singh S, Sandhu APS, Luthra S, et al (2024) Rebalancing the gut: glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health

Further studies are still needed to evaluate the benefits of GLP-1 receptor agonists in patients with polycystic ovary syndrome

Additionally, they often stand out as being more accessible, but do they deliver similar results

Brand-reported data: Customer counts, ratings, and outcome figures from Omzo's own lander and marketing materials

5.9% vs 2.8% weight loss at 24 weeks Upon examination of outcomes, the results were compelling

Healthcare providers often recommend continuing the program until clients achieve their target weight and establish healthier eating and activity patterns